Inception Sciences
Inception Sciences is a San Diego biotech venture studio founded in 2011 with Versant Ventures, using wetlab drug-discovery capabilities to create and launch standalone biotechnology companies addressing unmet medical needs across oncology, neurology, nephrology, and immunology, monetized through pharma build-to-buy acquisitions.
- Company typePrivate
- Founded2011
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Inception Sciences does
Inception Sciences (legal entity: Inception Therapeutics, Inc.) is a San Diego-based biotech venture studio founded in 2011 in partnership with Versant Ventures. The company operates as a dedicated company-creation engine, leveraging multi-disciplinary wetlab capabilities to identify scientific breakthroughs and technology platforms, and translating them into standalone biotechnology companies focused on diseases of significant unmet medical need. Its portfolio spans seven launched companies — Tempest Therapeutics (oncology), Chinook Therapeutics (kidney disease), Pipeline Therapeutics (neuro-regeneration), Ventus Therapeutics (innate immune system), Lycia Therapeutics (LYTAC extracellular protein degradation), Belharra Therapeutics, ADAXION Therapeutics, and Light Horse Therapeutics — plus two acquired entities (Inception 4 and Inception 5).
The company's underlying platform is its wetlab infrastructure and drug-hunting team, which validates therapeutic hypotheses and forms new entities around approved platforms or targets. Technology modalities span small molecule therapeutics, neuro-regenerative approaches (remyelination, synaptogenesis, axonal repair), and protein degradation (LYTAC), addressing oncology, nephrology, neurology, immunology, and ophthalmology. Versant Ventures serves as the founding and lead capital partner across company-creation rounds.
Inception's business model is transactional rather than product-recurring. Revenue is generated through build-to-buy acquisitions by pharmaceutical partners (e.g., Inception 5 to Roche in March 2018; Inception 4 to Ophthotech in November 2018), alongside equity participation, milestone economics, and likely management fees across the active portfolio. Companies launched by Inception have collectively raised over $250 million from pharma partners and other investors. Customer segments are pharmaceutical acquirers seeking novel therapeutic candidates and biotech investors seeking access to de-risked company-creation opportunities. Headcount remains modest at 11-50, consistent with a lean operating core that orchestrates portfolio companies rather than operating a commercial product line.
Inception Sciences firmographics
Firmographics- Name
- Inception Sciences
- Legal name
- Inception Therapeutics, Inc.
- Website
- https://inceptiontx.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Inception Sciences is a San Diego biotech venture studio founded in 2011 with Versant Ventures, using wetlab drug-discovery capabilities to create and launch standalone biotechnology companies addressing unmet medical needs across oncology, neurology, nephrology, and immunology, monetized through pharma build-to-buy acquisitions.
- Ownership category
- akta.pro rank
Inception Sciences industry classification
Industry- Product category
- Biotech Venture Studio
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Venture Studios / Company Builders (FSANAAAH)
- akta.pro secondary industries
- Corporate Venture Studios & Incubators (Build/launch ventures) (FSANAHAC), Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Inception Sciences is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Inception Sciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Company creation and acquisition: Inception creates new biotech companies and either sells them to pharmaceutical partners through build-to-buy arrangements or launches them as independent stand-alone companies. Revenue is generated through acquisition deals with pharma partners and subsequent value creation in portfolio companies.
Go-to-market motion1 record
Distribution channels1 record
Inception Sciences product offering
Product offeringCore offering
Inception Sciences operates as a biotech venture studio that builds and launches new biotechnology companies based on scientific breakthroughs and technology platforms. Leveraging multi-disciplinary wetlab capabilities and its partnership with Versant Ventures, Inception either creates and sells companies to pharmaceutical partners through build-to-buy arrangements or launches them as independent stand-alone companies. To date, the studio has launched seven companies that have collectively raised over $250 million in funding.
Product overview
Inception Sciences is a biotech venture studio that builds and launches new biotechnology companies. Founded in 2011 with Versant Ventures, Inception leverages multi-disciplinary wetlab capabilities to create transformational new biotechnology companies. The portfolio consists of ten distinct portfolio companies spanning multiple therapeutic areas (oncology, kidney disease, neurology, immunology) and technology platforms (small molecule therapeutics, neuro-regeneration, protein degradation). Inception has launched seven companies that have raised over $250 million in funding from pharma partners and other investors.
Differentiator
Problem solved
Functional benefit
Products and services
- Tempest Therapeutics Development-stage biotech company advancing small molecule therapeutics that modulate anti-tumor immunity pathways, launched by Inception Sciences.
- Chinook Therapeutics Biotech company developing precision medicines for diseases of the kidney, built and launched by Inception Sciences.
- Pipeline Therapeutics Platform identifying next generation neuro-regenerative therapies; developing first-in-class small molecules to promote remyelination, synaptogenesis and axonal repair, created by Inception Sciences.
- Ventus Therapeutics Biotech company discovering and developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer, built and launched by Inception Sciences with $60 million Series A funding.
- Lycia Therapeutics Biotech company developing first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases using LYTAC technology, launched by Versant Ventures based on Inception's platform with $50 million funding.
- ADAXION Therapeutics Portfolio company developing therapeutics, built and launched by Inception Sciences.
- Belharra Therapeutics Portfolio company developing therapeutics, built and launched by Inception Sciences.
- Light Horse Therapeutics Portfolio company developing therapeutics, built and launched by Inception Sciences.
Companies that use Inception Sciences
Customer profileSegments2 records
Ideal customer profiles2 records
Inception Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Inception Sciences partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
Inception Sciences competitors and assessment
Company assessmentEmerging players
- Curie.Bio: Curie.Bio is an emerging biotech founder studio providing wetlab, operational, and seed capital support to launch new therapeutic companies. It overlaps with Inception's core function of company creation with embedded scientific infrastructure.
Broad incumbents
- OrbiMed: OrbiMed is a dedicated healthcare investment platform that creates and funds biotech companies across stages. While broader in scope than Inception, it competes for the same founders, scientific breakthroughs, and pharma BD opportunities.
- New Enterprise Associates (NEA): NEA is a large multi-stage VC that has historically created and led biotech spinouts alongside dedicated healthcare partners. It competes with Inception's origination engine but operates as a broader investment platform rather than a focused company-builder.
Others
- Alexandria Venture Investments: Alexandria's venture arm provides founding and growth capital to biotech startups anchored in its innovation cluster campuses. It functions more as a capital partner and infrastructure provider than a company builder, but intersects with Inception's network of startup launch resources.
Direct peers
- BridgeBio Pharma: BridgeBio operates a hub-and-spoke model creating and incubating multiple genetically-targeted therapeutic companies under one platform. It is comparable to Inception in launching several biotech subsidiaries from a centralized origination and capital base.
- Atlas Venture: Atlas Venture actively builds biotech companies from inception within its own portfolio, partnering with repeat founders to launch and seed new therapeutic companies. It mirrors Inception's role as a hands-on company-creation partner with deep wetlab and operational support.
- Roivant Sciences: Roivant builds biotech 'Vants' through a similar company-creation engine model, launching multiple therapeutic-area-focused subsidiaries that are funded, operated, and selectively partnered or exited to pharma. It is the closest analogue to Inception's build-to-buy and stand-alone spinout strategy.
- Flagship Pioneering: Flagship is the archetypal biotech venture studio, originating platform companies like Moderna through in-house scientific exploration and company-building. It shares Inception's core competency of conceiving, validating, and launching new biotech entities with breakthrough science.
- ARCH Venture Partners: ARCH co-creates and co-founds biotech companies around breakthrough science and provides long-horizon capital across multiple portfolio entities. The model of originating and operating companies through to partnership or exit aligns with Inception's venture studio approach.
- Medicxi: Medicxi focuses on asset-centric company creation, spinning out single-product or platform companies from larger pharma partners. Its approach of building biotech companies around validated science and then partnering with pharma is closely aligned with Inception's build-to-buy origins.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Inception Sciences social profiles
Digital presenceInception Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Inception Sciences leadership team
Management profileNumber of profiles
Profiles4 records
Inception Sciences subsidiaries and ownership
Company hierarchySubsidiaries10 records
Inception Sciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Inception Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Inception Sciences
What does Inception Sciences do?
Inception Sciences operates as a biotech venture studio that builds and launches new biotechnology companies based on scientific breakthroughs and technology platforms. Leveraging multi-disciplinary wetlab capabilities and its partnership with Versant Ventures, Inception either creates and sells companies to pharmaceutical partners through build-to-buy arrangements or launches them as independent stand-alone companies. To date, the studio has launched seven companies that have collectively raised over $250 million in funding.
Is Inception Sciences a public or private company?
Inception Sciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Inception Sciences founded?
Inception Sciences was founded in 2011. It employs 11 to 50 people.
Where is Inception Sciences based?
Inception Sciences is headquartered in San Diego, United States, in the North America region.
How does Inception Sciences make money?
One revenue line is on record: company creation and acquisition.
Who are Inception Sciences's main competitors?
Curie.Bio is listed as an emerging player. Broad incumbents are OrbiMed and New Enterprise Associates (NEA). Alexandria Venture Investments is listed as an others. Direct peers are BridgeBio Pharma, Atlas Venture, Roivant Sciences, Flagship Pioneering, ARCH Venture Partners and Medicxi.
Does Inception Sciences have an API?
No public API is recorded for Inception Sciences.
What industry is Inception Sciences in?
Inception Sciences's product category is Biotech Venture Studio. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders, with a secondary code of FSANAHAC, Corporate Venture Studios & Incubators (Build/launch ventures). Its NAICS code is 541714 and its SIC code is 8731.